Machin, Abdulloh
3Departement Of Neuorology, Faculty Of Medicine, Universitas Airlangga - Dr. Soetomo General Hospital, Surabaya, Indonesia

Published : 23 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 23 Documents
Search

Effect of Simvastatin in Serum Interleukin-6 Level in Patients with Acute Ischemic Stroke Meo, Maria Lettisia; Machin, Abdulloh; Hasmono, Didik
Folia Medica Indonesiana Vol. 56 No. 3 (2020): September
Publisher : Universitas Airlangga

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (348.293 KB) | DOI: 10.20473/fmi.v56i3.24508

Abstract

Acute ischemic stroke is the leading cause of death and causing permanent disability in adults worldwide. In acute ischemic stroke, IL-6 levels positively correlated to more severe neurological deficits, more extensive brain damage and worse prognoses. The use of statin was associated with milder initial stroke severity, better functional outcome and lower mortality. This clinically randomized controlled trial study was aimed to analyze the serum levels of IL 6 in acute ischemic stroke patients who treated with Simvastatin 20 mg compare to placebo. Samples were taken using consecutive sampling method from hospitalized acute ischemic stroke patients in Neurology Department of Dr. Soetomo Teaching Hospital Surabaya and Airlangga University Hospital Surabayafrom August to November 2017. Total of 44 patients met the inclusion criteria, consisting of 22 patients in treatment group and 22 patients in control group.There were no significant difference in the characteristic of the patients in both groups (p>0.05). Averages of serum IL-6 in the control and the treatment group are 38.594±74.313 and 17.760±25.253(p=0,438) while averages of serum IL-6 post in the control group and the treatment are 46.586±103.484 and 15.275±17.183 (p=0,589). There were no significant level escalation in pre and post of control group (p = 0.205) and also no significant level reduction in pre and post of treatment group (p = 0.411), while the average difference in the control group (-7.992 + 78.912 pg/ml) and in the treatment group (2.485 + 23.738 pg/ml).
Inhibition of Neurogenesis and Induction of Glial Scar Formation by Neuroinflammation Following Ischemic Stroke: Evaluation of BDNF, GFAP, HMGB1 and TNF-α Expressions Aris Widayati; Fedik Abdul Rantam; Abdulloh Machin; Wibi Riawan
The Indonesian Biomedical Journal Vol 17, No 1 (2025)
Publisher : The Prodia Education and Research Institute (PERI)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.18585/inabj.v17i1.3439

Abstract

BACKGROUND: Ischemic stroke remains as a major health problem and one important process in Ischemic Stroke is neuroinflammation which has a principal role to maintain the balance of neurogenesis and neurodegeneration process in the brain. Neuroinflammation can lead to glial scar and inhibit neurogenesis processes which is needed for recovery neuron function. This study was conducted to observe the role of high mobility group box 1 (HMGB1) and tumor necrosis factor-α (TNF-α) as neuroinflammation markers to glial fibrillary acidic protein (GFAP) as glial scar marker and to brain-derived neurotrophic factor (BDNF) as neurogenesis marker in brain tissue following ischemic stroke.METHODS: Fifteen male Wistar rats were randomized to three groups; sham group, rats receiving occlusion and terminated 180 minutes later (group A), and rats receiving occlusion and terminated after 7 days (group B). Expressions of BDNF and BDNF mRNA were examined using immunohistochemistry (IHC) and Reverse Transcription Polymerase Chain Reaction (RT-PCR), respectively. While GFAP, HMGB1, TNF-α were assessed using IHC.RESULTS: Expression of BDNF was found lower in group A and group B than in sham group (5.20±1.924, 5.00±1.581, and 7.80±1.304, respectively; p=0.032). Expression of BNDF mRNA was found lower in group A and B than in sham group as well. While expression of GFAP was found higher in group A and B than in sham group (9.60±1.517, 11.40±2.074, and 5.20±1.48, respectively; p=0.000). Higher level of HMGB1 and TNF-α expressions were also found to in group A and group B than in sham group (9.3±1.528, 11.67±1.528, and 2.00±1.000, respectively; p=0.000 for HMGB1 and 6.33±1.155, 9.33±1.528, and 3.00±1.000, respectively; p=0.002 for TNF-α).CONCLUSION: The presence of low BDNF levels and high levels of GFAP, HMGB1 and TNF-α markers, possibly reflects inhibition of the neurogenesis process by neuroinflammation, and induced glial scar formation in ischemic stroke conditions after than 180 hours until 7 days. KEYWORDS: ischemic stroke, BDNF, GFAP, TNF-α, HMGB1
Clinical Improvement of Chronic Spinal Cord Injury and Immune Thrombocytopenia (ITP) with Corticosteroids Administration: A Case Report Talaway, Athalia Anastasia; Machin, Abdulloh; Kurniawan, Dedy
AKSONA Vol. 5 No. 2 (2025): JULY 2025
Publisher : Universitas Airlangga

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Highlight: Understanding the causes and associated factors of of spinal cord injury (SCI) is important. Immune thrombocytopenia may contribute to spinal cord injury. Corticosteroid therapy for ITP, has shown improved  clinical outcomes.   ABSTRACT Introduction: Spinal cord injury (SCI) is a significant medical condition caused by either traumatic events or pathological diseases, which leads to neurological deficits and various levels of motor, sensory, and autonomic dysfunction. Several treatments, including corticosteroids, have been proposed to reduce secondary neuronal damage,  but they are still controversial. Meanwhile, immune thrombocytopenia (ITP) can be treated with corticosteroids. The lack of research necessitates a review of steroids as a therapy for ITP and spinal cord trauma. Case: A 76-year-old woman complained of weakness in both legs for 15 days before being admitted to the hospital.The weakness was noticed after experiencing a fall. Additionally, the patient complained about having difficulty with both defecating and urinating. On examination,  muscle strength in the lower limbs was  graded 4 on both sides  according to the Medical Research Council (MRC) scale. The classification of the American Spinal Injury Association (ASIA) score was D, with neurological level injury (NLI) at the 6th thoracic level with immune thrombocytopenia (ITP). Considering the patient's condition, steroids were administered as a treatment option. Fortunately, the patient showed clinical improvements, with the ASIA score improving from D to E, suggesting a positive response to steroids and potential for neurological recovery. Conclusion: Steroids may be regarded as a possible treatment alternative for individuals suffering from spinal cord injuries and immune thrombocytopenic purpura (ITP).